Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a
human-optimization sciences company focused on applying novel and natural
treatment protocols to address a broad range of disorders and deficiencies with
an emphasis on psychedelic medicine, offers a timely line of organic, non-GMO
and vegan-certified products. In 2019, Johns Hopkins launched a center for
psychedelic research backed by private funders (http://ibn.fm/mtUhg). A recent article discussing the
company reads, “The focus of John Hopkin’s studies will be on the affect
psychedelics have on behavior, brain function, learning and memory, and the
brain’s biology and mood. New therapies and the effectiveness of psilocybin are
being explored for opioid addiction, Alzheimer’s disease, post-traumatic
stress, post-treatment Lyme disease syndrome, anorexia nervosa and alcohol use
related to depression. . . . The use of mushrooms in the health industry is
growing in credibility in both scientific and financial sectors, and laws
around the use of psilocybin mushrooms and their derivatives are changing. This
progress is providing companies such as SHRM the opportunity to support mental
health and develop new and improved treatments. The opportunities aren’t only
medicinal, so while Champignon is preparing large-scale production for clinical
settings, the company is also focused on retail opportunities in the health and
wellness market.”
To view the full article, visit http://ibn.fm/E4CfB
About Champignon Brands Inc.
Champignon Brands is a research-driven company specializing
in the formulation of a suite of medicinal mushrooms health products, as well
as novel ketamine, anaesthetics and adaptogenic delivery platforms for the
nutritional, wellness and alternative medicine industries. Via its vertically
integrated alternative medicine product range, Champignon is pursuing the
development and commercialization of rapid onset treatments capable of
improving health outcomes, such as depression and post-traumatic stress
disorder (“PTSD”), as well as substance and alcohol-use disorders. Under a
collaborative research agreement with the University of Miami’s Miller School
of Medicine, Champignon is conducting preclinical studies and eventual human
clinical trials, with the objective of demonstrating safety and efficacy of the
combination of psilocybin and cannabidiol in treating mTBI with PTSD or
standalone PTSD. Champignon continues to be inspired by sustainability, as its
medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For
more information, visit the company’s website at www.Champignonbrands.com.
NOTE TO INVESTORS: The latest news and updates
relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer excellent
growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment